Clinical Trial

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Study acronym: EPOCA
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The EPOCA study (Evaluation of a POlypill and Colchicine for risk reduction in patients with established Atherosclerotic cardiovascular disease) will be a randomized, superiority, parallel, 2x2 factorial, multicenter clinical trial which will include at least 7713 and up to a maximum of 10797 participants with established atherosclerotic cardiovascular disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-01-21.
Status change: Not Yet Recruiting → Recruiting 2025-09-12
Trial Details
NCT Number NCT06930885
Lead Sponsor Hospital do Coracao
Conditions Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)
Enrollment 7,713 participants
Start Date 2025-06-12
Primary Completion 2031-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-22